The effect of ω-fatty acids on mRNA expression level of PPARγ in patients with gastric adenocarcinoma.
BACKGROUND
The antineoplastic role of peroxisome proliferator-activated receptor gamma (PPARγ) ligandshas previously been demonstrated in several gastric cancer cell lines. Activation of PPARγ by polyunsaturated fatty acids (PUFAs) inhibits growth and proliferationof tumor cells. In this double-blind clinical study, we evaluate the effect of PUFAs on PPARγ mRNA expression in patients with gastric adenocarcinoma.


METHODS
A total of 34 chemotherapy-naive patients diagnosed with gastric adenocarcinoma were enrolled in the present study. According to treatment strategies, all subjects were divided into two groups, the first group (17 individuals) received cisplatin without supplements and the second group (17 individuals) received cisplatin plus orally administered PUFAs supplements for 3 weeks. The gastric biopsy samples were obtained from all participants before and after treatment, and PPARγ mRNA expression levels were evaluated by quantitative real-time polymerase chain reaction using validated reference genes.


RESULTS
Our findings revealed that PPARγ mRNA expression is significantly upregulated in group II afterreceiving cisplatin plus orally administered PUFAs supplements for three weeks (p < 0.0001), whereas PPARγ mRNA expression did not show significant alteration in group I after receiving cisplatin alone.


CONCLUSIONS
The results of the study evidence that PPARγ may act as a potential target for the therapy of human gastric adenocarcinoma.
Department of Biology, East Azarbaijan Science and Research Branch, Islamic Azad University, Tabriz 51388, Iran.
A
A
Hosseinzadeh
Liver and Gastrointestinal Disease Research Center, Tabriz University of Medical Sciences, Tabriz 51368, Iran.
M-H
MH
Somi
Department of Clinical Biochemistry, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz 51368, Iran.
H
H
Dolatkhah
Department of Internal Medicine, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz 51368, Iran.
A
A
Esfahani
Department of Medical Microbiology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz 51368, Iran.
H S
HS
Kafil
Department of Medical Genetics, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz 51368, Iran.
S M
SM
Ardebili
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002945:Cisplatin / Q000627:therapeutic use; D004311:Double-Blind Method; D005231:Fatty Acids, Unsaturated / Q000627:therapeutic use*; D005260:Female; D005753:Gastric Mucosa / Q000378:metabolism; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D006801:Humans; D008297:Male; D047495:PPAR gamma / Q000235:genetics*; D012333:RNA, Messenger / Q000235:genetics; D013270:Stomach / Q000187:drug effects / Q000473:pathology; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D015854:Up-Regulation / Q000187:drug effects*
D000970:Antineoplastic Agents; D005231:Fatty Acids, Unsaturated; D047495:PPAR gamma; D012333:RNA, Messenger; D002945:Cisplatin